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ABSTRACT
Background: Mutations in protein O-mannosyltransferases (POMTs) cause a heterogeneous
group of muscular dystrophies with abnormal glycosylation of -dystroglycan (dystroglycanopa-
thies). The wide spectrum of clinical severities ranges from Walker-Warburg syndrome (WWS),
associated with brain and eye abnormalities, to mild forms of limb girdle muscular dystrophy
(LGMD).
Objective: The aim of this study was to elucidate the impact of mutations in POMT1 on the clinical
phenotype.
Methods: We examined 2 patients with POMT1-associated -dystroglycanopathy, 1 displaying a
LGMD2K and 1 with a WWS phenotype. Using dermal fibroblasts, we analyzed the influence of the
POMT1 mutations on the glycosylation status of -dystroglycan, protein O-mannosyltransferase ac-
tivity, and the stability of themutant POMT1 protein.
Results: We report on novel compound heterozygous mutations in POMT1 (p.L171A and
p.A589VfsX38) that result in LGMD2K. We further demonstrate that a homozygous splice site
mutation of a recently identified WWS patient results in POMT1 p.del77-93. Using dermal fibro-
blasts, we show that mannosyltransferase activity is reduced in the patients and that stability of
POMT1 mutant proteins p.A589VfsX38 and p.del77-93 is significantly decreased.
Conclusions: Our results suggest that dermal fibroblasts can be applied to facilitate the diagnos-
tic analysis of dystroglycanopathy patients as well as to study the pathogenic mechanism of
POMT mutations. Characterization of the POMT1 substrate protein -dystroglycan and POMT in
vitro mannosyltransferase activity shows that the severity of the clinical phenotype of the pa-
tients analyzed is inversely correlated with POMT activity. Neurology® 2010;74:157–164
GLOSSARY
-DG  -dystroglycan; CMD  muscular dystrophies; LGMD  limb girdle muscular dystrophy; MLPA  multiplex ligation-
dependent probe amplification; POMT protein O-mannosyltransferase; WWSWalker-Warburg syndrome.
In humans, impaired protein O-mannosylation results in congenital muscular dystrophies
(CMD) that are referred to as secondary -dystroglycanopathies since a common pathologic
feature is the hypoglycosylation of -dystroglycan (-DG).1 The most severe disorder is
Walker-Warburg syndrome (WWS, OMIM 236670), characterized by CMD associated with
severe brain malformations and ocular abnormalities.2 WWS patients often die within the first
year of life. In contrast, the mildest disorders may not present until adulthood, such as limb-
girdle muscular dystrophy (LGMD), where neither brain nor eyes are affected.2 In between
these extremes, intermediate phenotypes have been described with CMD but mild mental
retardation and microcephaly.
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The protein O-mannosyltransferases POMT1
and POMT2 initiate the biosynthesis of
O-mannosyl glycans in the endoplasmic reticu-
lum.3 Mutations in the POMT1 (OMIM
607423) and POMT2 (OMIM 607439) genes
result in -dystroglycanopathies with overlap-
ping phenotypes. Distinct mutations in
POMT1 as well as POMT2 have been identified
in patients withWWS,muscle-eye-brain disease
(OMIM 253280), and mild forms of CMD
such as congenital muscular dystrophy with
mental retardation (CMD/MR), LGMD2K
(OMIM 609308), and LGMD2N.4-11 Based on
these observations, an inverse correlation be-
tween the degree of the remaining POMT activ-
ity and the severity of the clinical phenotype has
been postulated.7 However, so far, direct evi-
dence to support this hypothesis is lacking.
In this study, we determine POMT
O-mannosyltransferase activity in dermal fi-
broblasts of patients with different mutations
in the POMT1 gene. Our data show an in-
verse correlation between POMT activity and
the severity of the clinical phenotype in the
patients analyzed.
METHODS Patients. Patient 1 was originally identified as
LGMD2K. The 10-year-old boy was born at term after an un-
eventful pregnancy. Developmental milestones were delayed
with independent walking at 22 months. He developed second-
ary microcephaly with occipitofrontal circumference of 49 cm
(0.7 cm below third centile) at 6 years of age and is mentally
retarded with an IQ of 68 (80% interval, 63–79) according to
the Snijders-Oomen scale.12 Brain MRI scans did not reveal
structural changes. Serum creatine kinase levels were increased
(10 normal) and hypertrophy of the calf muscle and Gowers
sign with limb-girdle weakness was observed at 5 years. The
muscle biopsy at 3 years of age showed a myopathic pattern and
staining with a core antibody against -DG13 revealed a patchy
reduction of dystroglycan expression (data not shown).
Patient 2 presented with typical clinical signs of WWS. A
description can be found elsewhere.14
Cell lines and mutation analyses. Primary dermal fibro-
blasts and peripheral blood samples were obtained after in-
formed consent from the parents. Fibroblasts were grown in
Dulbecco modified Eagle’s medium supplemented with 10% fe-
tal calf serum, 60 g/mL penicillin, and 100 g/mL streptomy-
cin. Cell lines were cultivated at 37°C in a 5% CO2 incubator.
DNA was extracted from blood using standard protocols.
The 18 coding exons (exons 2–20) and intron–exon boundaries
of the POMT1 gene were amplified by PCR.5,14 PCR products
were sequenced using the ABI Prism BigDye Terminator v1.1
Cycle Sequencing Kit and analyzed on an ABI 3100 Avant se-
quencer (Applied Biosystems).
Multiplex ligation-dependent probe amplification (MLPA;
MRC-Holland) analysis for POMT1 was performed according
to manufacturers instructions. The kit contains probes for
POMT1 exons 2, 5, 17, and 19.
RT-PCR analyses. Total RNA extracts were reverse tran-
scribed using the Omniscript reverse transcriptase kit (Qiagen)
and oligo-dT primers. POMT1 cDNA was amplified by nested
PCR. Primer sequences are listed in table e-1 on the Neurology®
Web site at www.neurology.org. PCR products were separated
on 1.5% agarose gels or cloned into a TOPO-TA Cloning Vec-
tor (Invitrogen) for sequencing.
Antibody production. Anti-POMT1 antiserum was pro-
duced using a synthetic peptide corresponding to aa Arg-249 to
His-364 of mouse POMT1. The peptide was coupled to keyhole
limped hemocyanin and injected into rabbits. Antibodies were
purified using the peptide bound to cyanogen bromide-activated
Sepharose. Peptide synthesis, coupling, immunizations, and af-
finity purifications were done at Pineda Antikoerper Service
(Berlin/Germany).
Isolation of microsomal membrane fractions. Microso-
mal membrane fractions from cultured cells were isolated as de-
scribed previously.15 Microsomal membranes were resuspended
in 20 mM Tris-HCl pH 8.0, 10 mM EDTA. Protein concentra-
tion was determined using the Dc-Protein Assay (BioRad).
Wheat germ agglutinin–glycoprotein enrichment. Cul-
tured fibroblasts were washed with PBS containing protease in-
hibitors and harvested in the same buffer. Cell pellets were
processed as described elsewhere.16
Western blot analyses.Microsomal membranes (180g protein)
or wheat germ agglutinin–enriched glycoprotein fractions were sep-
arated on 8% SDS–polyacrylamide gels and transferred to nitrocel-
lulose. Polyclonal anti-POMT1, monoclonal anti--dystroglycan
(IIH6, Upstate), and polyclonal anti--dystroglycan (C20, Santa
Cruz Biotechnologies Inc.) antibodies were used. After decoration
with peroxidase-coupled secondary antibodies immunoreactivity
was visualized by chemiluminescence.
Assay for protein O-mannosyltransferase activity. Protein
O-mannosyltransferase activity was determined based on the
amount of [3H]-mannose transferred fromDol-P-[3H]-mannose to
an -DG glutathione-S-transferase fusion as described elsewhere.15
RESULTS Two novel compound heterozygous POMT1
mutations result in LGMD2K phenotype. Patient 1 was
originally identified as LGMD with mental retardation
(for details, see Methods). Sequencing of all coding ex-
ons of POMT1 revealed a novel heterozygous missense
mutation in exon 6 (data not shown) predicting a sub-
stitution of the conserved leucine residue Leu171
to alanine (p.L171A; NCBI reference sequence:
NP_009102.3) in the POMT1 protein (figure 1A).
This substitution was not observed in 51 healthy con-
trol subjects of European descent, and is not present in
SNP databases or human EST clones. Sequencing of
the coding exons of POMT2 and FKRP did not reveal
any mutations. Thus, we performedMLPA-analysis for
POMT1 which identified a partial heterozygous dele-
tion at the exon 19 probe (data not shown). For further
refinement, we performed RT-PCR analyses of
POMT1 transcripts. Total RNA from patient 1 and a
healthy control was reverse transcribed with oligo-dT
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primers. PCR reactions using primer combinations that
cover the POMT1 cDNA coding exons resulted in
products of the expected size (figure 1, B and D). How-
ever, amplification of the cDNA spanning exon 18 and
exon 19 (primers 1843F/2583R, figure 1B) besides the
expected 740 bp product resulted in an additional PCR
fragment of approximately 440 bp only in the patient
(figure 1D). The observed 300-bp difference between
these PCR products suggested a heterozygous deletion
of exon 18 to exon 19 in the patient. Sequencing of the
PCR products verified this deletion (figure 1C). The
lack of exon 18 to exon 19 in the POMT1 transcript
results in a frameshift mutation, causing an amino acid
change at position 589 from alanine to valine, followed
by a premature stop codon after 38 amino acids
(p.A589VfsX38).
A homozygous splice site mutation causes deletion of
exon 4 in POMT1-WWS patient. Patient 2 was re-
cently identified as WWS carrying a homozygous
base substitution at the 5-splice donor site of intron
4 (c.280  1GT; NM_007171).14 This mutation
is likely to impair the correct splicing of the POMT1
precursor mRNA. To further analyze the hypothe-
sized splicing defect, we characterized the POMT1
cDNA amplified from dermal fibroblasts of patient 2
and 2 control cell lines. PCR analysis using a primer
combination flanking exon 4 (tw297/tw298; figure
2A) resulted in the expected 252 bp fragments in the
control cDNAs, whereas in the WWS patient the
detected fragment is approximately 50 bp smaller
(figure 2B, upper panel). The observed difference in
the length of the PCR products suggested a deletion
of exon 4 (51 bp) in the patient’s mRNA. Deletion
of exon 4 is further supported by the fact that a RT-
PCR reaction using 1 primer within exon 4 (tw296
and tw298; figure 2A) resulted in the expected 197
bp POMT1 PCR fragment in the control cDNA, but
was absent in the patient (figure 2B, lower panel).
Sequence analysis of the 201 bp PCR fragment
(tw297 and tw298; figure 2, A and B) verified the
Figure 1 Novel POMT1 mutations result in LGMD2K
(A) Multiple sequence alignment, generated with the Clustal W algorithm27 using protein sequences of the following PMT4 subfamily19 members: Homo sapiens
POMT1 (NP_009102.3), Mus musculus POMT1 (NP_660127.1), Gallus gallus POMT1 (NP_001025856.1), Xenopus tropicalis (NP_001006756), Drosophila
melanogaster POMT1 (NP_524025.2), and Saccharomyces cerevisiae PMT4 (NP_012677.1). The black arrow indicates the position of the p.L171A mutation
that was detected in patient 1. Identical aa are shown in black, similar aa in gray. (B) Schematic representation of the human POMT1 cDNA covering the region
from exon 16 to exon 20. Positions of the primers used in (D) are indicated. (C) Sequencing of the 740-bp and 436-bp PCR fragments obtained from patient 1
confirm theabsenceof exon18 toexon19 fromthesmaller PCRproduct. (D)Amplificationof the cDNAregion containingexon18 toexon19 results in a740-bp
and436-bp PCRproduct (primers 1843F/2583R) indicating a heterozygous deletion of these exons in patient 1.
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deletion of exon 4 (figure 2C). Taken together, the
mutation of the 5-splice donor site of intron 4
causes skipping of exon 4 during processing of the
POMT1 precursor mRNA. Deletion of exon 4 re-
sults in the loss of 17 amino acids (p.del77-93)
within the putative catalytic domain between the
first and the second transmembrane domain of the
POMT1 protein.
Glycosylation of -DG and POMT O-mann-
osyltransferase activity correlate with the phenotype
of the secondary dystroglycanopathy. Both the
LGMD2K and the WWS patient carry POMT1mu-
tations; however, they both resemble opposite ends
of the clinical spectrum within the secondary
-dystroglycanopathies. To characterize in more de-
tail how the respective POMT1mutations contribute
to the clinical picture, we analyzed the O-
mannosylation status of the POMT1 substrate
-DG. Wheat germ agglutinin glycoprotein-
enriched fractions prepared from dermal fibroblast
cell lines were analyzed by Western blot. Antibodies
directed toward a so far unidentified O-mannosyl-
linked glyco-epitope on -DG (IIH6) detected
-DG variants between 100 and 125 kDa in control
cells (figure 3; lane 1). Similar variants were detected
in extracts derived from the LGMD2K patient but to
a highly reduced amount (figure 3; lane 2). In con-
trast, no IIH6 positive -DG was detectable in the
WWS patient (figure 3; lane 3). Equal loading was
confirmed by detection of -dystroglycan. These
findings confirm a direct correlation between the se-
verity of the clinical phenotype and the degree of
functionally O-mannosylated -DG.
We further analyzed whether differences in the
O-mannosylation state of -DG are reflecting differ-
ences in POMT activity in patient cells. To this end,
we measured in vitro POMT mannosyltransferase
activity in dermal fibroblasts of the patients. First, we
adapted an enzymatic assay that was previously de-
scribed for human embryonic kidney fibroblast
(HEK 293) cells and lymphoblasts.15,17 POMT activ-
ity in human dermal fibroblasts highly exceeds the
activity in HEK 293 cells (data not shown).15 A lin-
ear increase in the transfer of radioactive mannose to
the mannosyl acceptor was observed within the range
of 20 g to 120 g of microsomal membranes (fig-
Figure 2 Genetic analysis of patient 2 (Walker-Warburg syndrome)
(A) Schematic representation of the applied RT-PCR strategy. (B) c.280  1GT results in skipping of exon 4. PCR with
primers tw297/tw298 produces a 252-bp fragment using cDNA derived from 2 control cell lines and a 201-bp in cDNA
prepared from patient 2. The absence of the 197-bp RT-PCR product of patient 2 upon amplification with the primer
combination tw296/tw298 confirmed the absence of exon 4. (C) Sequencing of the 201-bp PCR fragment obtained in
patient 2 confirmed the absence of exon 4 from the smaller PCR product.
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ure 4A). To ensure that the mannose donor is not
limiting to the reaction, increasing amounts of Dol-
P-Man were added. As shown in figure 4A, excess of
the mannosyl donor was achieved between 1 pmol
and 2 pmol. According to these results, enzyme activ-
ity was determined using 2 pmol of Dol-P-[3H]Man
and 80 g of microsomal membranes derived from
fibroblasts of controls and patients. Although
POMT activities among the tested control cell lines
showed some variability, a clear reduction was ob-
served in the analyzed patients. When compared to
the controls, 40% residual activity was detected in
the LGMD2K patient (figure 4B). In contrast, in the
WWS patient described above (POMT1 p.del77-93)
only 6% residual POMT activity was detected. An
additional WWS patient4 (POMT1 mutation:
G76R; NP_009102.3) showed 10% residual
POMT activity.
Our data show that the degree of -DG
O-mannosylation and the enzymatic activity of the
mutated POMT1 protein inversely correlate with
the phenotypic severity observed in the patients
analyzed.
Amino acid deletions affect stability of mutant
POMT1 proteins. Since POMT1 mutations differ-
ently affect enzymatic activity, we further analyzed
their impact on the POMT1 protein. We performed
Western blot analysis of microsomal membranes
from control and patient-derived dermal fibroblast
cells. For POMT1 detection, we generated antibod-
ies directed against a 15 amino acid peptide (Arg-249
to His-364) located in the central hydrophilic do-
main of mouse POMT1 (described in Methods).
This domain is not affected in the analyzed POMT1
patients. As shown in figure 5 (lane 1), on Western
blot wild-type POMT1 can be detected with an ap-
parent molecular weight of 85 kDa. In accordance
with the two POMT1 mutant alleles, 2 proteins are
observed in the LGMD2K patient. The 85 kDa pro-
tein corresponds to the POMT1 p.L171A amino
acid substitution, whereas the 71 kDa protein repre-
sents the p.A589VfsX38 mutant form of POMT1
(figure 5; lane 2). Comparing the quantities of the 2
proteins, the amount of p.A589VfsX38 POMT1 ap-
pears to be significantly lower, suggesting decreased
stability of the mutant protein. Remarkably, in the
WWS patient POMT1 p.del77-93 could not be de-
tected (figure 5; lane 3), although the mutant protein
lacking amino acids 77–93 does contain the anti-
POMT1 epitope. Our data show that deletion of dif-
ferent regions of POMT1 affects protein stability. In
contrast, amino acid substitution p.L171A results in
a stable but less active POMT1 protein coinciding
with the milder phenotype of the LGMD2K patient.
DISCUSSION We identified 2 novel POMT1 mu-
tations that in combination result in LGMD2K phe-
notype (figure 1). Mutation p.A589VfsX38 causes
deletion of the C-terminal 158 amino acids includ-
ing 2 putative transmembrane spans and the loop6
domain (figure e-1). This deletion significantly af-
fected POMT1 protein stability (figure 5). In con-
trast, amino acid substitution p.L171A resulted in
decreased O-mannosyltransferase activity without af-
fecting POMT1 stability (figures 4 and 5). Leu171 is
conserved in vertebrate and invertebrate POMT1s
(figure 1A) which provides further pathologic evi-
dence. In addition, we characterized a POMT1 mu-
tation p.del77-93 that results in WWS14 (figure 2).
This mutation has also been reported in 2 other
WWS patients.18 The POMT1 p.del77-93 protein
lacks 17 amino acids within a hydrophilic domain
between 2 putative transmembrane spans close to the
N-terminus of the protein (figure e-1). This region
has been demonstrated to be essential for protein
O-mannosyltransferase activity in yeast.19 Western
blot analyses suggest that the mutation affects pro-
tein stability and that the POMT1 p.del77-93 mu-
tant protein is degraded in the patient (figure 5).
We determined POMT activity in dermal fibro-
blast cells of these patients. In agreement with the
lack of the POMT1 protein, the WWS patient (fig-
ures 3 and 4) is characterized by abolished in vitro as
Figure 3 O-mannosylation of-DG inPOMT1-
associated-dystroglycanopathies
Western blot analysis of wheat germ agglutinin–glycopro-
tein enriched extracts prepared from control, LGMD2K, and
Walker-Warburg syndrome (WWS) patient-derived dermal
fibroblasts. Blots were probed with IIH6-antibodies that
specifically recognize an O-mannosyl linked glycoepitope
on -DG (anti-glyco -DG). To ensure equal protein loading
we analyzed an identical blot was probed with
-dystroglycan specific antibodies (anti--DG).
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well as in vivo O-mannosylation of -DG. In mam-
mals, POMT1-POMT2 complexes are formed and
complex formation is a prerequisite for full enzy-
matic activity.15,20 However, POMT2 might be enzy-
matically active in the absence of POMT1 and
therefore account for the low residual in vitro activity
detected (6% residual activity) in the WWS sam-
ples.21 Studies with protein O-mannosyltransferases
(PMTs) of yeast substantiate this assumption. In
yeast, Pmt1p and Pmt2p form heteromeric com-
plexes; however, the individual Pmt-proteins show
low levels of in vitro activity, even in the absence of
their complex partner.22,23 Compared to the WWS
patient, in vitro as well as in vivo O-mannosylation
of -DG is less affected in the LGMD2K patient
(figures 3 and 4).
Using dermal fibroblasts as enzyme source to
measure POMT activity, we provide direct evidence
that POMT activity correlates with the severity of
symptoms of the analyzed dystroglycanopathy pa-
tients (figure 4). Future studies with larger patient
cohorts will be necessary to corroborate our hypoth-
esis of inverse correlation between residual enzymatic
POMT activity in POMT1 patients and the clinical
phenotype. Recently it was shown that POMT activ-
ities are abolished in lymphoblasts from various pa-
tients with POMT1 or POMT2 mutations.17 Even
more, lymphoblastoid cell lines from a LGMD2K
patient carrying a homozygous POMT1 pA200P
mutation5 showed almost no POMT activity as it
was observed in WWS cases.17 The reported POMT
activity in lymphoblastoid cells of those patients
(non detectable to0.004 pmol/hour/mg protein17)
was at least 10 times lower compared to activities in
patients’ dermal fibroblasts analyzed in this study
(figure 4). Thus, it is probably difficult to resolve
differences in POMT activity in patient lympho-
blasts. Comparative histologic analyses of muscle
cross sections stained with antibodies directed to-
ward an O-mannosidically linked glycoepitope of
-DG showed that staining intensities correlated
with the severity of the clinical phenotype of the pa-
tients.24,25 Thus, so far only indirect evidence sug-
gested a correlation between the clinical phenotype
Figure 4 POMT enzyme activity in POMT1 associated -dystroglycanopathies
(A) Correlation of POMT enzyme activity with the amount of microsomal membranes and Dol-P-[3H]Man were recorded to
determine the linear range for the POMT enzyme assay. (B) POMT activities in control cells and patient-derived dermal
fibroblasts. POMT activity was based on the rate of radioactive [3H]mannose transfer from Dol-P-[3H]Man (125,000 dpm/
pmol) to a GST--DG fusion protein.
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and POMT activity in POMT1 and POMT2 associ-
ated -dystroglycanopathy patients.
Our study shows that dermal fibroblasts provide a
source to detect defects caused by mutations in
POMTs. This is especially important with respect to
diagnosis of CMD patients. Besides POMT1 and
POMT2, 4 additional genes—POMGnT1 (OMIM
606822), Fukutin-related protein (OMIM 606596),
Fukutin (OMIM 607440), and LARGE (OMIM
603590)—have been established to cause secondary
-dystroglycanopathies in humans.2 Since there is a
strong overlap in the clinical features between muta-
tions in these genes, sequencing of up to 6 genes is
necessary to identify the causative mutation. Further-
more, recent studies9,17,26 demonstrated intragenic
deletions and splicing abnormalities due to deep in-
tronic mutations of POMT1 and POMT2, which
have been missed by genomic sequencing of exons
and flanking intronic sequences. Therefore, testing
of POMT enzymatic activity provides a valuable di-
agnostic tool for this group of patients. Here we
show that POMT activity can be measured in con-
trol and patient primary dermal fibroblasts (figure
4B). This assay represents an accurate functional
method to prescreen patients harboring POMT1 and
POMT2 mutations among those with suspected or
confirmed -dystroglycanopathies. Besides the mea-
surement of POMT activity, the use of fibroblasts
will also allow the evaluation of -DG which is ex-
pressed in these cells (figure 3).27 Therefore, the use
of dermal fibroblast cells may circumvent the need
for invasive muscle biopsies when clinical findings
are suggestive of secondary -dystroglycanopathies
and exonic sequencing has not revealed pathogenic
mutations.
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Editor’s Note to Authors and Readers: Levels of Evidence in Neurology®
Effective January 15, 2009, authors submitting Articles or Clinical/Scientific Notes to Neurology®
that report on clinical therapeutic studies must state the study type, the primary research ques-
tion(s), and the classification of level of evidence assigned to each question based on the AAN
classification scheme requirements. While the authors will initially assign a level of evidence, the
final level will be adjudicated by an independent team prior to publication. Ultimately, these levels
can be translated into classes of recommendations for clinical care. For more information, please
access the articles and the editorial on the use of classification of levels of evidence published in
Neurology.1-3
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